This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class TNM002; Huadao Biopharma launching a STAR Market IPO process with…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for…
John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment of the CDMO market and the link between insufficient manufacturing…
The Minister of Health of the Republic of Turkey, Dr Fahrettin Koca, provides an overview of the current state of the Turkish healthcare ecosystem, highlighting its opportunities and challenges. He…
The past 5 decades have seen monumental strides in healthcare; from the discovery that aspirin prevents blood clotting to the eradication of smallpox. In this exclusive interview, Thomas Cueni, director…
Jerry Radich of the Fred Hutchinson Cancer Center, writing in the February 2026 edition of DIA’s Global Forum magazine, lays out a framework for taking cutting-edge cancer therapies – currently…
Ahead of this year’s International Women’s Day on March 8th, Unjela Kaleem highlights the disproportionate impact of cancer on women, especially those in developing countries. Kaleem – drawing on 20+…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Insilico Medicine’s partnership with Hengtai Biotech to co-develop an AI-discovered NLRP3 inhibitor for CNS disorders and Ellipses Pharma’s licensing…
Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World…
See our Cookie Privacy Policy Here
